| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2873320 | The Annals of Thoracic Surgery | 2014 | 6 Pages |
Abstract
Calcineurin inhibitor-free immunosuppression with everolimus is an effective and safe option in selected maintenance HTx patients. Most adverse effects under everolimus occurred early after conversion and in most cases resolved without intervention within a few weeks. Refining selection criteria may help both in identifying patients who will profit most from switching and in alleviating the need to reintroduce CNI therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Markus A. MD, Henryk A. MD, Stefan MD, Susanne MS, Mortimer Phil MD, Angelo M. MD, Joerg MD,